Seedlabs

Same-Day Impulse Session: In-Clinic 1064 nm tPBM Adjunct for Adult ADHD

An in-clinic laser treatment for adults with ADHD that includes a quick test to show immediate results.

A standardized in-clinic session that applies 1064 nm laser light to the right prefrontal cortex of adults with ADHD, bookended by a quick computerized impulsivity test so each patient leaves with a same-day before/after report — positioned as an acute adjunct, especially for medicated patients with residual impulsivity.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderAdult ADHD clinics and behavioral health providers offering a non-pharmacological adjunct service

Concept

A turnkit service for adult ADHD clinics: a fixed-protocol 1064 nm transcranial photobiomodulation (tPBM) session applied to the right prefrontal cortex, with a 5-minute continuous performance task (CPT) administered before and after so every patient gets a same-day impulsivity report (correct rejections and false alarms).

  • Who it's for: adults with ADHD, prioritizing those already on medication whose impulsivity is not fully controlled — the trial's exploratory finding that medicated participants improved more after tPBM (p = 0.049) supports adjunct positioning, though the authors flag it for cautious interpretation. It also serves patients who want a drug-free acute option.
  • When it's used: scheduled around demand spikes — exam weeks, deadline sprints, high-stakes work periods — because the demonstrated effect is acute (single session), not a claimed durable cure.
  • What clinics get: a certified device kit (wavelength, power, and scalp site fixed to match the trial), operator training, and a session-report generator; aggregated before/after CPT data builds a registry that can feed the repeated-session studies the trial authors explicitly call for.
  • Honest labeling: the service sells the measured acute effect — performance normalization, not supernormal enhancement, since active-tPBM participants reached levels comparable to non-ADHD peers — and does not claim lasting benefit until multi-session trials exist.

Why now

  • First RCT evidence in adults with ADHD: a single active 1064 nm tPBM session to the right PFC improved CPT correct rejections by 51% vs sham, bringing performance to non-ADHD levels (p = 0.017, Cohen's d = 0.93) [0].
  • The effect has a measurable physiological basis: fNIRS showed increased prefrontal oxyhemoglobin (p = 0.011) and total hemoglobin (p = 0.038) vs sham [0].
  • Safety and breadth: no adverse events across both trial stages (223 and 52 participants), and no sex differences in the effect [0].
  • Room in the market: a component network meta-analysis concluded the comparative benefits and harms of adult ADHD interventions remain unclear [1], while 15.5 million U.S. adults (6.0%) carry a current ADHD diagnosis [5] — a large population for a well-measured, non-drug adjunct.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 3 papers93

A highly focused, evidence-backed clinical service that leverages a specific RCT result to offer acute impulsivity reduction as a measurable adjunct to ADHD care.

Evidence strength
5/5
The idea is directly derived from a specific RCT showing a 51% improvement in CPT correct rejections and corresponding fNIRS oxygenation increases using the exact 1064 nm wavelength and right PFC target.
Market pull
4/5
There is a massive addressable market (15.5M adults) and a clear pain point in stimulant shortages and residual impulsivity in medicated patients.
Novelty & moat
5/5
Unlike the existing catalog ideas which focus on screening, prescribing, or behavioral training, this introduces a novel hardware-based neurostimulation mechanism for acute symptom management.
Feasibility
4/5
The protocol is already standardized in the research; the MVP requires only the existing laser hardware and a basic CPT software implementation.
Wedge clarity
5/5
The 'Same-Day Impulse Session' is a sharp, high-value entry point that provides immediate, quantifiable feedback to the patient via the before/after report.
Simplicity / focus
5/5
The product is a single, well-defined clinical session rather than an over-scoped platform, focusing exclusively on acute impulsivity.

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Vielight Inc.company

    Makes 1064 nm transcranial photobiomodulation devices — the exact device class validated by this trial in adult ADHD (Cohen's d = 0.93); a certified clinic protocol would open a clinical channel beyond the consumer wellness market.

  • ADHD 360company

    UK adult ADHD provider whose medicated patients with residual impulsivity are the best-fit users; adding a measured in-clinic adjunct differentiates its service with a same-day visible effect.

  • Dr. Ned Hallowellindividual

    Prominent adult-ADHD psychiatrist whose treatment centers could offer a non-drug, same-day-measured option to patients seeking alternatives or additions to stimulants.

  • ADDA (Attention Deficit Disorder Association)organization

    Nonprofit serving adults with ADHD; a no-adverse-event, non-drug acute option is directly relevant to its members, including those who avoid or cannot tolerate stimulant medication.

Research it builds on

  1. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023
    Brooke S. Staley, Lara R. Robinson, Angelika Hartl Claussen et al. · 2024 · 87 citations
    All ideas from this paper →
  2. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis
    Edoardo Giuseppe Ostinelli, Marcel Schulze, Caroline Zangani et al. · 2024 · 79 citations
    All ideas from this paper →
  3. Transcranial photobiomodulation improves prefrontal oxygenation and impulse control in adults with ADHD: a randomized controlled trial
    Farzad Salehpour, Douglas W. Barrett, Anagh Mirji et al. · 2026 · 3 citations
    All ideas from this paper →
Leave feedback
feasibility